Uncovering the Epigenetic Regulators of Lung Cancer
As a physician scientist, Hui-Zi Chen, MD, PhD, approaches lung cancer from two angles – by harnessing the latest techniques to understand cancer’s basic biology and by working to translate those results to help the patients she treats.
In the clinic, she sees the effect that small cell lung cancer (SCLC) has on patients and their families. Though this subtype of lung cancer accounts for only 15 percent of all new cases of lung cancers diagnosed each year, it is so aggressive that less than 10 percent of those diagnosed survive more than five years.
As an assistant professor of hematology and oncology at the òòò½ÎÑ (MCW), Dr. Chen has dedicated her career to understanding the biology of this cancer.
“As a physician scientist, I have my feet in both worlds,” she says. “I want to develop better therapies for my lung cancer patients, so I go back to the lab and ask questions like, ‘Why is it resistant to treatment? Why does it metastasize early?’ Our team really wants to leverage what we learn to best help our patients.”
Armed with tools to study the epigenetic regulators of cancer, she’s on the forefront of understanding the drivers of therapeutic resistance – and how those pathways might lead to new therapies.
Studying the Poster Child of Precision Medicine
Growing up as the daughter of a physician, Dr. Chen spent many nights sleeping on a cot at the hospital while her mother worked night shifts. She also visited her scientist father at his lab, intrigued by his work there.
“I decided I wanted to have a career in either science or medicine, but then I found that a hybrid MD/PhD program would allow me to do both,” she says.
Early on in her career, her focus turned to lung cancer. Unlike other cancers, pathology alone does not drive diagnosis and treatment for this disease.
“Lung cancer has many different categories of driver mutations, many of which are matched to a specific therapy,” she says. “Those therapies can be incredibly effective when the right mutation is matched to the right therapy. In that way, lung cancer is the .”
As a clinician, Dr. Chen is thankful she can treat patients with such specific therapies. Still, gaps remain, particularly for SCLC patients who don’t typically benefit from targeted therapies. Dr. Chen knew she wanted to perform research to address these gaps.
Understanding How the Epigenome Regulates Lung Cancer

In her lab, Dr. Chen uses SCLC cell lines and organoids derived from patient tumors to study epigenetic regulators of cancer.
Research has shown that understanding how proteins affect gene expression without changing the DNA itself is key to understanding how SCLC transforms from one subtype to another.
This phenomenon, called lineage plasticity, is an important mechanism of treatment resistance. With a new , Dr. Chen is studying the pathways affected by one such protein called KMT2D, which is mutated in a unique subset of SCLC patients.
Furthermore, SCLC is a “transcriptionally addicted” cancer, meaning it relies on hyperactive gene expression to grow and survive. Using techniques like CUT&RUN (Cleavage Under Targets & Release Using Nuclease), Dr. Chen and her team are also discovering new , which could provide precise targets for treatments and predict drug resistance.
While Dr. Chen leads clinical trials at MCW that have the potential to benefit all lung cancer patients, her ultimate goal is to develop a clinical trial for a novel lung cancer therapy that was born from findings discovered in her lab.
“The reason we need to perform basic science experiments is so we can discover a particular cancer’s Achilles’ heel. Then we can leverage our understanding of the disease to develop precise treatments without creating excess toxicity,” she says.
Such precision therapy might directly halt tumor growth, sensitize a tumor to other treatments such as immunotherapy, or alter the tumor’s microenvironment such that it is more difficult for the tumor to survive. The hope of precision therapies motivates her patients to contribute to research, as well.
“When I tell my patients that I’m also a researcher, they often say that they want to donate their blood or tissue so that we can study it in the laboratory,” she says. “It gives them hope to be cared for by someone who has dedicated her clinical and research career to understanding their disease.”
A Collaborative Atmosphere on an Upward Trajectory
Since arriving at MCW in 2021, Dr. Chen has found a collaborative research atmosphere at the school that has propelled her career forward.
“If I’m missing expertise in a specific technique or subject, I can just walk down the hall and find another researcher – also a friend – who works in that area,” she says. “What I enjoy most about my job is that we don’t do science in a silo. We give each other a lot of support – both among researchers and patients.”
In her laboratory in the Michels Center for Cancer Discovery, Dr. Chen is part of a team that is aiming to become a National Cancer Institute-designated cancer center.
“Here at MCW, we are on an upward trajectory,” she says. “There’s just a lot of enthusiasm and momentum. We have all grown together in the past few years and we have created this big, collaborative family of researchers that makes MCW the right place to be.”